Cinven Limited is a global private equity firm founded in 1977, with offices in nine international locations in Guernsey, London, New York, Paris, Frankfurt, Milan, Luxembourg, Madrid, and Hong Kong that acquires Europe and United States–based corporations, and emerging market firms that fit with their core businesses, and necessitate a minimum equity investment of €100 million or more. As of 2024, it has €44 billion in assets under management.
Bain Capital and Cinven, the private equity firms behind the German pharmaceutical company Stada, are reportedly preparing for an initial public offering (IPO) that could take place as early as Wednesday.
The move comes as Stada seeks to capitalize on favorable market conditions. The IPO is expected to attract significant investor interest, given the company's strong performance and growth potential in the pharmaceutical sector.
Details regarding the IPO, including pricing and the number of shares to be offered, have yet to be disclosed. However, the anticipation surrounding the offering highlights the ongoing trend of private equity firms looking to exit investments through public listings.
Investors and market analysts will be closely watching Stada's IPO, as it could set a precedent for other private equity-backed companies considering similar moves in the near future.
For those interested in following this development and other private equity news, a subscription to AltAssets is required for full access to articles and insights.
We tailor your onboarding experience to match what you're looking for. Tell us more about yourself and your team to help us out.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
